The past decade has seen growing interest in ovarian stimulation protocols with GnRH antagonists in an effort to reduce the incidence of potential complications, such as cyst formation and ovarian hyperstimulation syndrome, and thus improve the clinical experience for patients. Current assisted reproductive technique programmes also increasingly utilize milder protocols for ovarian stimulation. In a recently published randomized controlled trial, we showed that low-dose hCG can be utilized clinically to replace recombinant FSH (rFSH) during the late follicular phase in a GnRH antagonist protocol. This regimen leads to a significant reduction in rFSH consumption, while the ICSI outcome, in terms of oocyte yield and ongoing pregnancy rate, remains comparable with the control regimen of rFSH plus a GnRH antagonist. In the present study, the influence of the administration of low-dose hCG on the endometrium was assessed. A comparison was made between two protocols for ovarian stimulation with GnRH antagonists, namely the classical protocol with rFSH and the protocol with low-dose hCG in the late follicular phase. We analysed the morphological pattern and gene expression profile of human endometrium on the day of oocyte retrieval. No morphological differences were observed and only a minimal set of 65 differentially expressed probe sets between the treatment groups were identified, enabling a similar efficacy to support implantation.
Introduction
The use of controlled ovarian stimulation (COS) for assisted reproductive techniques (ARTs) aims to recruit a cohort of mature oocytes that can be fertilized resulting in a number of good-quality embryos to be selected for embryo transfer. Besides the impact on the quality of oocytes and embryos obtained, ovarian stimulation results in supraphysiological concentrations of ovarian steroid hormones and paracrine mediators, resulting in an abnormal steroid milieu.
Along with the administration of gonadotrophins to induce multiple follicular development, GnRH analogues (i.e. GnRH agonists or GnRH antagonists) are added for the prevention of premature LH surges in IVF. GnRH agonist administration causes gonadotrophin suppression via pituitary desensitization, after an initial short period of gonadotrophin hypersecretion. In contrast, GnRH antagonists cause immediate and rapid gonadotrophin suppression, by competitive occupancy of the GnRH receptor. Systematic reviews and meta-analyses Tarlatzis et al., 2006) have shown that GnRH antagonist protocols significantly shorten the treatment period and reduce the inconvenience for the patient, although no clear benefit in terms of live birth rate has been attributed to either GnRH analogue (Al-Inany and Aboulghar, 2002; Kolibianakis et al., 2006) .
The effect of ovarian stimulation on endometrial maturation at oocyte pick-up cycles in which an embryo transfer is performed has been studied in both GnRH agonist protocols (Ubaldi et al., 1997) and GnRH antagonist protocols (Kolibianakis et al., 2002) . Endometrial advancement on the day of oocyte retrieval is present in all cycles stimulated with rFSH in combination with GnRH antagonists. Moreover, if the endometrium at oocyte pick-up shows an advancement of more than 3 days compared with the expected chronological date, no pregnancy is achieved. In addition to this study, Van Vaerenbergh et al. (2009) demonstrated that endometrial gene expression discriminates between women with and without histologically advanced endometrial maturation exceeding 3 days on the day of oocyte retrieval. Despite advances in new stimulation protocols, the detrimental effect on endometrial receptivity and therefore on implantation may not be neglected, since pregnancy rates in ARTs are still relatively low and have not significantly increased in the last decade (Bourgain and Devroey, 2003; Nyboe Andersen et al., 2009) . Regarding new protocols of ovarian stimulation, the approach to use low doses of hCG in the late follicular phase has been evaluated previously, and several of these studies, using a variety of protocol modifications, have been published (Filicori et al., 2006; Koichi et al., 2006; Blockeel et al., 2009) . Prior to these studies, FSH was considered the only stimulatory factor needed for ovulation induction, and was known to act through specific receptors present on granulosa cells of ovarian follicles. The role of LH, the other critical hormone involved in the control of the human menstrual cycle, is in dominant follicle selection and maturation at a time of declining FSH levels, somewhat later in the follicular phase. Granulosa cells of larger follicles (i.e. follicles of .10 mm in diameter) become responsive to LH through the expression of LH/hCG receptors induced by FSH and estrogens, thus making them sensitive to LH activity stimulation. A corollary of these findings is the capacity of LH activity to stimulate follicle function and growth independently of FSH administration, once LH receptors are expressed by granulosa cells. In a GnRH antagonist protocol, we demonstrated that the administration of 200 IU/day of hCG can be successfully applied in patients undergoing ART to substitute for recombinant FSH in the final days of ovarian stimulation .
The present study is a continuation of the previous randomized trial , set up to compare two protocols for ovarian stimulation with GnRH antagonists, and aims to assess the influence of the administration of low-dose hCG in the late follicular phase before final oocyte maturation on the endometrium. We studied the morphological pattern and gene expression profile of human endometrium on the day of oocyte retrieval in patients of both treatment groups.
Materials and Methods

Study design
The study presented here is a prospective trial and was conducted in 35 women seeking infertility treatment between May 2008 and December 2008. The trial was set up to compare two protocols for controlled ovarian hyperstimulation with antagonists. In one group of patients, a standard antagonist protocol was applied (group A, the rFSH group), while patients allocated to a second group underwent a modified treatment protocol with low-dose hCG as a substitute for rFSH (group B, the hCG group). Randomization took place after the final outpatient clinic visit. A computer-generated list was used for randomization, concealed from the physician, but not from the study nurse. Each patient was enrolled into the study only once. All patients gave written informed consent. The study received institutional review board approval by the Ethics Committee of the Centre for Reproductive Medicine, UZ Brussel, Belgium.
The patients included in the study were women below 36 years of age who underwent a first or second treatment cycle of IVF with ICSI. Patients were excluded from the study if they requested preimplantation genetic diagnosis, had an azoospermic partner or had a serum FSH level on Day 3 of the menstrual cycle of more than 12 IU/l. A single embryo transfer policy was applied in all cycles.
Multifollicular ovarian stimulation
Ovarian stimulation with recombinant FSH (rFSH) in a GnRH antagonist protocol has been described previously (Papanikolaou et al., 2005a,b) . Briefly, on Day 2 of the menstrual cycle (Day 1 of the stimulation), daily injections of the recombinant follicle-stimulating hormone, follitropin beta (Puregon w , NV Organon, Oss, The Netherlands) were initiated at a dose of 200 IU. On Day 7 of the cycle (Day 6 of the stimulation), subcutaneous administration of the antagonist, ganirelix, (Orgalutran w , NV Organon, Oss, The Netherlands) was started at a daily dose of 0.25 mg in the morning. From Day 7 of the cycle onwards, ovarian ultrasound scans to assess follicular growth and blood sampling for estradiol (E 2 ), progesterone, FSH, LH and hCG levels, were performed on a daily basis. This decision to perform daily monitoring allowed us to adjust the dose of rFSH if necessary and to discover eventual signs of premature luteinization. In the hCG group, the administration of rFSH was discontinued when at least six follicles of ≥12 mm were observed and E 2 levels were higher than 600 ng/l. Recombinant FSH was then substituted by 200 IU hCG (Pregnyl w , NV Organon, Oss, The Netherlands), until final oocyte maturation. In both groups, final oocyte maturation was induced by the administration of 10 000 IU of hCG (Pregnyl), as soon as three follicles of 17 mm in diameter were visualized on ultrasonography. Oocyte -cumulus complexes (OCC) were recovered 36 h after the hCG administration. Luteal phase support consisted of 600 mg of vaginally administered micronized natural progesterone (Utrogestan, Besins International, Paris, France) per day. To assess the treatment outcome, serum hCG was measured 14 and 17 days after oocyte retrieval.
Embryo culture, evaluation and embryo transfer
Procedures for ICSI were carried out as described by Van Landuyt et al. (2005) . Embryo quality was assessed daily until the time of transfer or cryopreservation (in case of spare embryos), as described by Papanikolaou et al. (2005a,b) . The embryo quality on Day 5 was assessed according to the criteria of Gardner and Schoolcraft (1999) .
Endometrial biopsy and histological assessment
Aspirational biopsy of the endometrium was performed using the Pipelle de Cornier (CCD International, Paris, France) on the day of oocyte retrieval. All specimens were divided into two pieces: one piece was fixed immediately in Bouin's solution and sent for histopathological examination. All biopsies were processed for light microscopy and dated through semiquantitative analysis according to the criteria of Noyes et al. (1950) by one observer (C.B.) who was blinded to the groups. Dating of the endometrial sample was done in relation to the day of the administration of hCG.
Gene expression profiling
The second part of the endometrial biopsy was cryopreserved immediately for microarray analysis. Biopsies from 10 patients (5 patients from each treatment group), without pregnancy following embryo transfer, were analysed for gene expression. These patients were matched according to age, histological dating criteria, cycle characteristics and embryo quality (Table I) . Histological dating ranged from the late proliferative phase to the luteal phase Day 3 (Table II) . No samples histologically dated as more than 3 days advanced were included in the microarray analysis (Table III) . RNA extraction was performed using the RNeasy Mini kit (Qiagen, Valencia, CA, USA) following the manufacturer's protocol. Total RNA concentration was measured with the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and integrity of the RNA samples was determined using the Agilent 2100 Bioanalyzer with the RNA 6000 Nano Kit (Agilent Technologies Inc., Palo Alto, CA, USA). All samples had a 260/280 absorbance ratio around 2.0 and an RNA Integrity Number .8.5 (Schroeder et al., 2006) . The gene expression analysis was performed with Affymetrix Human Genome (HG) U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, CA, USA) and the resulting image files were analysed with Affymetrix Endometrial gene expression after ovarian stimulation outliers were found after normalization. Transcripts were considered as differentially expressed when all of the following criteria were met: (i) present progesterone calls in all samples in either one of the two groups; (ii) consistent decreased or increased change in expression for pair-wise comparisons between the two selected groups; (iii) a mean absolute value of the signal log ratio ≥0.5; this equals a fold change ratio (FC) of 1.4 or higher and (iv) Student's t-test with a significant result (P ≤ 0.05). The data files have been deposited in NCBI's Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) (Edgar et al., 2002) according to MIAME guidelines and are accessible through GSE18 557.
Validation with real-time PCR
Selected differentially expressed genes with highly significant FC ratios were validated with quantitative real-time PCR. A two-step real-time quantitative PCR was performed on the microarray samples and on the samples from non-pregnant women from both treatment groups (in total n ¼ 21; n ¼ 13 from group A, n ¼ 8 from group B). A reversetranscription reaction from total RNA was achieved with the HighCapacity cDNA Archive kit (Applied Biosystems, Foster City, CA, USA) following the manufacturer's protocol. The real-time quantitative PCR was performed with the appropriate TaqMan Gene Expression Assay (Applied Biosystems), containing two unlabelled primers and one TaqMan FAM dye-labelled MGB probe. Glyceraldehyde-3-phosphate dehydrogenase was chosen as the endogenous control. All real-time PCR assays were run using the TaqMan Universal PCR Master Mix plus AmpErase UNG (Applied Biosystems) on the 7900HT Fast Real-Time PCR System. Thermal cycling parameters were set as follows: 2 min at 508C (AmpErase UNG activation), 10 min at 958C (AmpliTaq Gold activation), followed by 40 cycles of denaturation, annealing and extension (15 s at 958C and 1 min at 608C, respectively). No-template and noreal-time controls were included to verify the quality and cDNA specificity of the primers. All samples were analysed in triplicate. The relative quantification was performed by the standard curve method. Real-time PCR data were analysed with Student's t-tests (P ≤ 0.05).
Outcome measures
The following information was gathered: endometrial dating in both treatment groups and gene expression profile in both treatment groups. Furthermore, demographic and clinical characteristics such as age, weight, height and basal hormonal serum values; the number of cumulus-oocyte complexes (COC), duration of the stimulation and the total cumulative dose of rFSH consumed were documented, along with the fertilization and implantation rates in each treatment group. It is important to note that the implantation rate equals the pregnancy rate since only one embryo was transferred.
Results
Clinical results
A total of 35 patients were randomly assigned to either the study or the control group. There were no significant differences between the groups with regard to demographic characteristics. As shown in Table I , the mean female age in the rFSH group was 30.4 + 4.0 years, compared with 30.5 + 2.5 years in the hCG group (NS, not significant).
In the rFSH group, one patient did not start stimulation because of a spontaneous pregnancy and another two patients did not undergo oocyte retrieval [one patient developed ovarian hyperstimulation syndrome (OHSS) and one patient was cancelled because of low response]. In the low-dose hCG group, two patients became pregnant spontaneously and one patient could not start because of elevated FSH. One patient did not undergo oocyte retrieval but underwent a rescue insemination instead. There was protocol violation in three patients in the latter group.
In the control group, two patients did not reach the stage of embryo transfer due to failed blastocyst development. In the study group, there was no blastocyst development in three patients. Details referring to the stimulation are summarized in Table I . Overall treatment duration (days of stimulation) did not significantly differ. Obviously, the duration of rFSH administration in the hCG group was significantly lower than in the rFSH group. HCG was administered in the hCG group for 2.1 + 0.6 days. The total dose of rFSH consumed was significantly lower in the hCG group: 1218 (SD 244) versus 1693 (SD 281), P , 0.001.
The number of OCC obtained at retrieval and the fertilization rate were similar in both groups. One patient in the rFSH group and three patients in the hCG group became pregnant (NS; Table I ). None of the patients who underwent oocyte retrieval developed a moderate or severe forms of OHSS.
All patients underwent an endometrial biopsy on the day of oocyte retrieval. Histological results are shown in Table II . There is no difference in both groups in terms of histological dating of the endometrium on the day of oocyte retrieval. Figures 1 and 2 show representative biopsies from both a non-pregnant and pregnant woman of the hCG treatment group, where maturation corresponds to Day 2 of the luteal phase and the late proliferative phase, respectively.
Endometrial gene expression
Gene expression analysis was performed with samples from five nonpregnant patients of the hCG group and five non-pregnant patients of the rFSH group. Table III describes the histology and RNA quality of the 10 microarray samples. The analysis showed a significant Figure 1 Representative endometrial biopsy on the day of oocyte retrieval from a woman of the hCG group, who remained nonpregnant. Pseudo-stratification with subnuclear vacuoles is seen in the glands (arrow). The maturation corresponds to Day 2 of the luteal phase (haematoxylin and eosin staining, magnification ×200). differential expression of 65 probe sets between the hCG and the rFSH group, with 21 up-regulated and 44 down-regulated in the hCG group (Tables IV and V) . Unsupervised principal component analysis (PCA) with GeneSpring GX 7.3 was applied to reduce the multidimensional gene expression data into three dimensions. It showed a heterogenous expression pattern with no specific clusters for group A or B. The list of genes was subjected to pathway analysis with Ingenuity. Pathways and networks involved in cell cycle regulation and apoptosis, and Notch signalling were associated with the differentially regulated genes.
Validation was performed with real-time PCR on selected genes, with high FC ratios, on all available non-pregnant patient samples from both treatment groups (n ¼ 13 from group A and n ¼ 8 from group B, n ¼ 21 in total). These FCs observed by PCR were consistent with those from the microarray data: THSD4 (thrombospondin, type I, domain containing 4) [FC microarray: 22.7 
Discussion
To the best of our knowledge, this is the first study to assess the impact on endometrial gene expression of a standard rFSH stimulation protocol, compared with a 200 IU hCG regimen in the late follicular phase, in a GnRH antagonist protocol. No difference in terms of histological dating of the endometrium on the day of oocyte retrieval could be demonstrated, and full HG gene expression analysis showed a significant differential expression of 65 probe sets only.
In our previous study , it was demonstrated that the administration of 200 IU/day of hCG can be safely applied in patients undergoing ART to substitute for rFSH in the final days of ovarian stimulation in an antagonist protocol. The approach to use low doses of hCG in COS protocols with GnRH agonists and antagonists has been tested in the past (Kosmas et al., 2009) . Moreover, the applicability of this hCG protocol in a routine clinical setting was established by Filicori et al. (2005) . GnRH antagonists are increasingly used in normal responders in clinics worldwide. Nevertheless, there is still controversy about whether pregnancy rates after IVF treatment in a GnRH antagonist protocol are comparable to those in GnRH agonist protocols for IVF (Al-Inany et al., 2006; Kolibianakis et al., 2006) . The application of GnRH antagonists is associated with a significantly lower probability of OHSS associated with hospital admission ; additionally, the treatment burden and patients' distress is also significantly less when using a GnRH antagonist protocol compared with a GnRH agonist protocol . The hCG protocol used in the present study could be even more beneficial with respect to a decreased consumption of gonadotrophins, which confers a significant reduction on the treatment cost .
Treatment and stimulation characteristics observed in this study correspond to the findings reported in the previous pilot study with low-dose hCG in the late follicular phase .
It has been speculated that endometrial quality may be more detrimentally affected in GnRH antagonist-based compared with GnRH agonist-based stimulation protocols . Nevertheless, comparing the endometrial development in the early and midluteal phases in women undergoing COS following a GnRH antagonist protocol or a GnRH agonist protocol, no relevant alteration has been observed. Moreover, the endometrial development after a GnRH antagonist mimics the natural endometrium more closely than after a GnRH agonist protocol (Simon et al., 2005) . Although this would appear to suggest that the GnRH antagonists in clinical use have no additional effect on endometrial receptivity at the gene level, possible subtle effects may have been masked by the effect of exogenous progesterone on gene expression (Macklon et al., 2008) .
The effect of hCG administration in the follicular phase on the endometrium is largely unknown. The only reported data involve the administration of hCG on Day 14 of an artificial cycle, where an advanced endometrial maturation and decreased epithelial mitotic activity was seen compared with control cycles without hCG (Fanchin et al., 2001) . The lack of further data makes it extremely difficult to speculate on possible differences in gene expression. Other literature data assessing the effect of hCG on the endometrium have been mainly performed in in vitro studies on the endometrial epithelial cells only (Perrier d'Hauterive et al., 2004) ; the differential expression of leukaemia inhibitory factor and interleukin 6, as described in that study, could not be confirmed in the present in vivo material.
Although still to be elucidated, the expression of the LH/hCG receptor could be a marker of endometrial receptivity. It is increasingly clear that hCG in the luteal phase intervenes in the regulation of endometrial differentiation with a positive impact at the different steps of implantation, tissue remodelling and angiogenesis (Perrier d'Hauterive et al., 2007) . From previous studies, it was also suggested that hCG in the follicular phase positively influences implantation rates (Filicori et al., 2005) . As a corollary of this, the introduction of hCG in the late follicular phase could enhance uterine receptivity and therefore play a significant role in implantation.
In the present study, results of endometrial dating according to histological criteria indicated a large proportion of advanced endometrial development in both treatment groups. This finding corresponds well with the general trend observed in the literature: an advanced endometrium just before or at oocyte retrieval, but 'in phase' endometrium in the early luteal phase (Bourgain and Devroey, 2003) . Our results suggest that histological morphology is independent of the stimulation type used in the late follicular phase, namely rFSH or hCG.
Prolongation of the follicular phase by delaying hCG administration results in a higher incidence of endometrial advancement on the day of oocyte retrieval (Kolibianakis et al., 2005) . Based on these data, the daily current practice has been changed recently, resulting in less premature secretory changes in the endometrium, as confirmed in the present study, where 30% of the endometria display a lateproliferative growth pattern. Therefore, a comparison of the gene expression profile with previously published data on the day of oocyte retrieval (Van Vaerenbergh et al., 2009 ) cannot be made.
Endometrial gene expression analysis on the day of oocyte retrieval resulted in the identification of a limited group of genes as differentially regulated between the rFSH treatment and the hCG treatment. PCA showed no clustering within this group of genes. However, the limited list of 65 differentially expressed probe sets may show more subtle effects of the treatment protocol on the endometrial development. From the 65 genes, the most relevant ones already described to be related to implantation were THSD4 (Vazquez et al., 1999; Porter et al., 2005; Wen et al., 2006) , NLRP2 (Zhang et al., 2008) and ALDH1A3 (Burney et al., 2007; Macklon et al., 2008) . However, validation with quantitative PCR on more samples (n ¼ 21) demonstrated no significant FCs, showing that these three genes are not significantly different between both groups. Other interesting genes in the list of differentially expressed genes are Jagged 1 (JAG1) and HEY1 (hairy/ enhancer of split-related repressor protein 2; HERP2). These genes are part of the Notch receptor pathway, which plays a key role in cell differentiation. The Notch ligand JAG1 and the Notch target gene HEY1 are expressed in human endometrial epithelial cells (Mikhailik et al., 2009) .
In conclusion, the replacement of rFSH by 200 IU of hCG per day in the late follicular phase of a GnRH antagonist protocol results in a similar endometrial histological and gene expression pattern. From the subtle changes in 65 genes, we do not expect a significant modulation of endometrial receptivity in these cycles.
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